Melding a new 3-dimensional agarose colony assay with the Emax model to determine the effects of drug combinations on cancer cells

Technology in Cancer Research and Treatment

Volumn 8, Issue 2, 2009, Pages 163-176

  Kajiwara, Yoshinori ^a   Panchabhai, Sonali ^a   Liu, Diane D ^a   Kong, Maiying ^b   Lee, J Jack ^a   Levin, Victor A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Alpha difluoromethylornithine; Carboplatin; Docetaxel; Glioma; Vorinostat

Indexed keywords

AGAROSE; CARBOPLATIN; DOCETAXEL; EFLORNITHINE; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL SIZE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RESPONSE; ENZYME ASSAY; GLIOMA; HUMAN; HUMAN CELL; THREE DIMENSIONAL IMAGING; TUMOR VOLUME;

EID: 65949095895     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460900800210     Document Type: Article

References (64)

1. Kajiwara, Y., Panchabhai, S., Levin, V. A. A new preclinical 3-dimensional agarose colony formation assay. Technol Cancer Res Treat 7, 329-334 (2008).
2. Kleihues, P., Louis, D. N., Scheithauer, B. W., et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61, 215-225; discussion 226-1219 (2002). (Pubitemid 34212595)
3. Louis, D. N., Ohgaki, H., Wiestler, O. D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114, 97-109 (2007).
4. Levin, V. A., Chamberlain, M. C., Prados, M. D., et al. Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors. Cancer Treat Rep 71, 459-464 (1987).
5. Prados, M., Rodriguez, L., Chamberlain, M., et al. Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha- difluoromethylornithine. Neurosurgery 24, 806-809 (1989). (Pubitemid 19157083)
6. Levin, V. A., Uhm, J. H., Jaeckle, K. A., et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine- procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 6, 3878-3884 (2000).
7. Levin, V. A., Hess, K. R., Choucair, A., et al. Phase III randomized study of postradiotherapy chemotherapy with combination alpha- difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9, 981-990 (2003). (Pubitemid 36323701)
8. Oredsson, S. M., Deen, D. F., Marton, L. J. Decreased cytotoxicity of cis-diamminedichloroplatinum(II) by alpha-difluoromethylornithine depletion of polyamines in 9L rat brain tumor cells in vitro. Cancer Res 42, 1296-1299 (1982).
9. Tofilon, P. J., Oredsson, S. M., Deen, D. F., Marton, L. J. Polyamine depletion influences drug-induced chromosomal damage. Science 217, 1044-1046 (1982).
10. Tofilon, P. J., Deen, D. F., Marton, L. J. alpha-Difluoromethylornithine- induced polyamine depletion of 9L tumor cells modifies drug-induced DNA cross-link formation. Science 222, 1132-1135 (1983). (Pubitemid 14206946)
11. Chang, B. K., Gutman, R., Chou, T. C. Schedule-dependent interaction of alpha-difluoromethylornithine and cis-diamminedichloroplatinum(II) against human and hamster pancreatic cancer cell lines. Cancer Research 47, 2247-2250 (1987). (Pubitemid 17099179)
12. Milam, K. M., Deen, D. F., Marton, L. J. Cell proliferation and polyamine metabolism in 9L cells treated with (2r,5r)-6-heptyne-2,5-diamine or alpha-difluoromethylornithine. Cell Tissue Kinetics 22, 269-277 (1989).
13. Chang, B. K., Black, O., Gutman, R. Inhibition of growth of human or hamster pancreatic cancer cell lines by alpha-difluoromethylornithine alone and combined with cis-diamminedichloroplatinum(II). Cancer Research 44, 5100-5104 (1984). (Pubitemid 15204471)
14. Allen, E. D., Natale, R. B. Effect of alpha-difluoromethylornithine alone and in combination with doxorubicin hydrochloride, cis-diamminedichloroplatinum (II), and vinblastine sulfate on the growth of P3J cells in vitro. Cancer Res 46, 3550-3555 (1986).
15. Kurihara, H., Matsuzaki, S., Tamura, M., et al. alpha- Difluoromethylornithine increases the anti-tumor effect of cis- diamminedichloroplatinum in G-XII rat glioma. Neurologia Medico-Chirurgica 35, 215-220 (1995).
16. Bhalla, K. N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23, 3971-3993 (2005).
17. Dokmanovic, M., Marks, P. A. Prospects: histone deacetylase inhibitors. J Cell Biochem 96, 293-304 (2005).
18. Johnstone, R. W., Licht, J. D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13-18 (2003).
19. Minucci, S., Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6, 38-51 (2006). (Pubitemid 43054973)
20. Yoo, C. B., Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5, 37-50 (2006).
21. Qiu, Y., Kung, H. J. Signaling network of the Btk family kinases. Oncogene 19, 5651-5661 (2000).
22. He, L. Z., Tolentino, T., Grayson, P., et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108, 1321-1330 (2001). (Pubitemid 33107760)
23. Coffey, R. N., Watson, R. W., Fitzpatrick, J. M. Signaling for the caspases: their role in prostate cell apoptosis. J Urol 165, 5-14 (2001).
24. Zhu, Y. P., Stovall, J. J., Butler, L., et al. Comparison of two immobilization techniques using portal film and digitally reconstructed radiographs for pediatric patients with brain tumors. Int J Radiat Oncol Biol Phys 48, 1233-1240 (2000).
25. Le Roith, D., Bondy, C., Yakar, S., et al. The somatomedin hypothesis: 2001. Endocr Rev 22, 53-74 (2001). (Pubitemid 32187803)
26. Eyupoglu, I. Y., Hahnen, E., Buslei, R., et al. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 93, 992-999 (2005). (Pubitemid 40695758)
27. Ugur, H. C., Ramakrishna, N., Bello, L., et al. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. J Neurooncol 83, 267-275 (2007). (Pubitemid 46952237)
28. Yin, D., Ong, J. M., Hu, J., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13, 1045-1052 (2007). (Pubitemid 46340384)
29. Van Schaeybroeck, S., Karaiskou-McCaul, A., Kelly, D., et al. Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy. Clin Cancer Res 11, 7480-7489 (2005). (Pubitemid 41507709)
30. Ryan, Q. C., Headlee, D., Acharya, M., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23, 3912-3922 (2005). (Pubitemid 46218694)
31. Forsyth, P., Cairncross, G., Stewart, D., et al. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs 14, 203-206 (1996). (Pubitemid 26340689)
32. Sanson, M., Napolitano, M., Yaya, R., et al. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 50, 245-249 (2000). (Pubitemid 32192876)
33. McGrogan, B. T., Gilmartin, B., Carney, D. N., McCann, A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta (2007).
34. Kajiwara, Y., Panchabhai, S., Levin, V. A. A New Preclinical 3-Dimensional Agarose Colony Formation Assay. Tech Cancer Res Treat; in press (2008).
35. Lee, J. J., Kong, M., Ayers, G. D., Lotan, R. Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat 17, 461-480 (2007). (Pubitemid 46699662)
36. Oehlert, G. W. A note on the Delta Method. The American Statistician 46, 27-29 (1992).
37. Normand, S-LT. Tutorial in biostatistics mea-analysis: Formulating, evaluating, combining, and reporting. Statistics in Medicine 18, 321-359 (1999).
38. Marton, L. J., Levin, V. A., Hervatin, S. J., et al. Potentiation of the antitumor therapeutic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor. Cancer Res 41, 4426-4431 (1981).
39. Alhonen-Hongisto, L., Deen, D. F., Marton, L. J. Time dependence of the potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity caused by alpha-difluoromethylornithine-induced polyamine depletion in 9L rat brain tumor cells. Cancer Res 44, 1819-1822 (1984). (Pubitemid 14145720)
40. Alhonen-Hongisto, L., Hung, D. T., Deen, D. F., Marton, L. J. Decreased cell kill of vincristine and methotrexate against 9L rat brain tumor cells in vitro caused by alpha-difluoromethylornithine-induced polyamine depletion. Cancer Res 44, 4440-4442 (1984). (Pubitemid 14008761)
41. Oredsson, S. M., Pegg, A. E., Alhonen-Hongisto, L., et al. Possible factors in the potentiation of 1-(2-chloroethyl)-3-trans-4-methylcyclohexyl-1- nitrosourea cytotoxicity by alpha-difluoromethylornithine in 9L rat brain tumor cells. European Journal of Cancer & Clinical Oncology 20, 535-542 (1984). (Pubitemid 14138860)
42. Hunter, K. J., Deen, D. F., Marton, L. J. Differential response to 1,3-bis (2-chloroethyl)-1-nitrosourea in drug-resistant and -sensitive 9l rat brain tumor cells pretreated with alpha-difluoromethylornithine and 6-thioguanine. International Journal of Cancer 44, 658-660 (1989).
43. Cohen, A. R., Pietronigro, D. D., Cravioto, H., Flamm, E. S. Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intra-arterial BCNU. Journal of Neurosurgery 65, 671-678 (1986). (Pubitemid 17177518)
44. Paliwal, J., Janumpalli, G., Basu, H. S. The mechanism of polyamine analog-induced enhancement of cisplatin cytotoxicity in the U-251 MG human malignant glioma cell line. Cancer Chemother Pharmacol 41, 398-402 (1998). (Pubitemid 28095756)
45. Zuo, C. J., Wang, P. J., Shao, C. W., et al. CT-guided percutaneous ethanol injection with disposable curved needle for treatment of malignant liver neoplasms and their metastases in retroperitoneal lymph nodes. World J Gastroenterol 10, 58-61 (2004).
46. Butler, L. M., Zhou, X., Xu, W. S., et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99, 11700-11705 (2002).
47. Richon, V. M., Sandhoff, T. W., Rifkind, R. A., Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97, 10014-10019 (2000).
48. Saunders, L. R., Verdin, E. Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors. Mol Cancer Ther 5, 2777-2785 (2006).
49. Gerner, E. W., Meyskens, F. L. Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4, 781-792 (2004).
50. Hobbs, C. A., Paul, B. A., Gilmour, S. K. Elevated levels of polyamines alter chromatin in murine skin and tumors without global changes in nucleosome acetylation. Exp Cell Res 290, 427-436 (2003).
51. Kim, M. S., Blake, M., Baek, J. H., et al. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63, 7291-7300 (2003). (Pubitemid 37413470)
52. Hershberger, P., Owonikoko, T. K., Ramalingam, S., Belani, C. P. The effect of p53 gene status on the interaction of vorinostat (suberoylanilide hydroxamic acid-SAHA) with carboplatin in non-small cell lung cancer. J Clin Oncol 25, 581s (2007).
53. Markman, M., Kennedy, A., Webster, K., et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 19, 1901-1905 (2001). (Pubitemid 32702533)
54. Rein, D. T., Kurbacher, C. M., Breidenbach, M., et al. Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study. Gynecol Oncol 87, 98-103 (2002). (Pubitemid 36027108)
55. Kupryjanczyk, J., Kraszewska, E., Ziolkowska-Seta, I., et al. TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer 8, 27 (2008).
56. Kushner, D. M., Connor, J. P., Sanchez, F., et al. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol 105, 358-364 (2007). (Pubitemid 46613899)
57. Smith, J. A., Ngo, H., Martin, M. C., Wolf, J. K. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol 98, 141-145 (2005). (Pubitemid 40826431)
58. Ishimoto, O., Sugawara, S., Inoue, A., et al. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer. J Thorac Oncol 1, 979-983 (2006). (Pubitemid 47181366)
59. Kasahara, K., Kimura, H., Shibata, K., et al. A phase II study of combination chemotherapy with docetaxel and carboplatin for patients with advanced or metastatic non-small cell lung cancer. Anticancer Res 26, 3723-3728 (2006).
60. Kataoka, K., Suzuki, R., Taniguchi, H., et al. Phase I/II trial of docetaxel and carboplatin as a first-line therapy in patients with stage IV non-small-cell lung cancer. Lung 184, 133-139 (2006). (Pubitemid 44222460)
61. Hubbert, C., Guardiola, A., Shao, R., et al. HDAC6 is a microtubule-associated deacetylase. Nature 417, 455-458 (2002). (Pubitemid 34563539)
62. Matsuyama, A., Shimazu, T., Sumida, Y., et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. Embo J 21, 6820-6831 (2002). (Pubitemid 36014554)
63. Bali, P., Pranpat, M., Swaby, R., et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 11, 6382-6389 (2005). (Pubitemid 41262970)
64. Das, B., Rao, A. R., Madhubala, R. Difluoromethylornithine antagonizes taxol cytotoxicity in MCF-7 human breast cancer cells. Oncol Res 9, 565-572 (1997). (Pubitemid 127787906)